5 stories mentioning IMMPUpdated 43d ago
Every FINWIRES story that references IMMP, newest first.
Immutep (IMMP) shares were up over 5% in Wednesday trading after Maxim Group upgraded the stock to buy from hold, with a price target of $1.50.Trading volume stood at more than 232,000 shares, compared with a daily average of about 13.5 million.Price: $0.37, Change: $+0.02, Percent Change: +5.17%
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 2.9%.GoodRx (GDRX) shares climbed up 3.8% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 2.2%.Immutep (IMMP) shares doubled after the firm said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.
Health care stocks were rising pre-bell Wednesday with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Mesoblast (MESO) shares were up more than 4% after the company said it acquired an exclusive worldwide license to a chimeric antigen receptor technology platform for augmentation of therapeutic mesenchymal lineage stromal cell products.ARS Pharmaceuticals (SPRY) stock was up more than 1% after the company said Health Canada has approved its neffy 2mg nasal spray for the emergency treatment of anaphylaxis.Immutep (IMMP) shares rose by more than 178% after the company said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa for the treatment of soft tissue sarcoma, a rare cancer.
Immutep (IMMP) said early Wednesday that the United States Food and Drug Administration has granted orphan drug designation to eftilagimod alfa for the treatment of soft tissue sarcoma, a rare cancer.Shares of the company surged more than 58% in recent premarket activity.The move follows clinical data from a phase 2 trial that evaluated efti in combination with radiotherapy and Keytruda (pembrolizumab). In 38 patients, the study met its primary endpoint, demonstrating a median tumor hyalinization/fibrosis of almost 52%, exceeding the pre-specified target of 35% and historical benchmarks of about 15% with radiotherapy alone. Tumor hyalinization/fibrosis refers to healing.The company said the results were observed across multiple sarcoma subtypes and showed immune activation consistent with efti, with a favourable safety profile and no delays to planned surgery.Price: $0.495, Change: $+0.1838, Percent Change: +58.80%
